The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADVFN Regulatory News (AFN)

Share Price Information for ADVFN (AFN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.50
Bid: 10.00
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.00 (10.00%)
Open: 10.50
High: 10.50
Low: 10.50
Prev. Close: 10.50
AFN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

6 Mar 2023 07:00

RNS Number : 9043R
ADVFN PLC
06 March 2023
 

 

6 March 2023

For immediate release

ADVFN PLC

("ADVFN" or the "Group")

Unaudited Interim Results for the Six Months Ended 31 December 2022

 

ADVFN today announces its unaudited interim results for the six months ended 31 December 2022 (the "Period").

 

Chief Executive's Statement

 

On behalf of the board of Directors, I am delighted to report that our recent fundraising has been a success. As announced in January, we raised £4.52 million through the Open Offer and which will provide us with the necessary resources to pursue our strategic objectives and drive growth.

 

We are grateful to our investors for their confidence in our ability to execute on our mission and deliver value to our customers. With this infusion of capital, we can invest in our business to drive growth and scale our operations to meet the demand for our product offerings.

 

Looking ahead, we have a positive outlook for the future. Our roadmap includes expanding our product portfolio, entering new geographic markets, and strengthening our partnerships with our key stakeholders. We are confident that these initiatives will drive further growth and establish our position as a leader in our industry.

 

Financial performance

 

The half-year financial report for the Period is in line with the statements made in the Open Offer document and our trading update. The changes in management, structure and employees disrupted our normal workflow during the Period and made it a challenge for the Company to meet its financial targets. However, the Company remains optimistic and with the Open Offer completed and the changes we are working on, we have confidence in our new team. The Company acknowledges that changes take time and appreciates the efforts being made by the team.

 

The key financial performance for the Period is summarised in the table below:

 

Six Months ended 31 December 2022

Six Months ended 31 December 2021

£'000

£'000

Revenue

3,061

4,228

Profit / (loss) for the period

)616)

202

Operating profit / (loss)

(622)

229

Profit per share - basic (see note 3)

(2.36) p

0.77p

 

The Board is not recommending a dividend.

 

Outlook

As we move forward into 2023, I am excited to share with you our plans to build new products and invest in our operations to drive growth and deliver value to our users and shareholders.

 

With the proceeds from our recent fundraising efforts, we will be able to accelerate our product development efforts and plan to bring innovative new solutions to market. Our R&D team is working tirelessly to identify emerging trends and technologies that will enable us to stay ahead of the curve and deliver the next generation of products and services.

 

We also plan to invest in our operations to improve our efficiency and scalability. This will involve upgrading our infrastructure, streamlining our processes, and investing in our people to ensure that we have the talent and capabilities to support our growth ambitions.

 

As we pursue these initiatives, we remain committed to maintaining a disciplined approach to capital allocation and managing our resources in a way that delivers the best returns for our shareholders. We will closely monitor our progress and adjust our strategy as necessary to ensure that we achieve good results.

 

In summary, we are confident that our focus on product innovation, operational excellence, and disciplined capital allocation will enable us to achieve our growth objectives and create long-term value for all our stakeholders.

 

We thank our shareholders for their continued support, and we look forward to providing further updates on our progress in the months ahead.

 

 

Amit Tauman

CEO

6 March 2023

For further information please contact:

ADVFN plc

Amit Tauman (CEO)

 

 

+44 (0) 203 8794 460

Beaumont Cornish Limited (Nominated Adviser)

Michael Cornish

Roland Cornish

+44 (0) 207 628 3396

Peterhouse Capital Limited (Broker)

Eran Zucker / Lucy Williams / Rose Greensmith

+44 (0) 207 469 0930

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. The person who arranged for the release of this announcement on behalf of the Company was Amit Tauman, Director.

 

A copy of this announcement will be available on the Group's website: 

 www.advfnplc.com

 

Condensed interim consolidated income statement

 

 

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2022

2021

2022

£'000

£'000

£'000

unaudited

unaudited

audited

Notes

 

Revenue

 

3,061

4,228

7,848

Cost of sales

 

(196)

(162)

(374)

 

Gross profit

 

2,865

4,066

7,474

 

Amortisation of intangible assets

 

(91)

(138)

(256)

Administrative expenses

 

(3,390)

(3,699)

(7,176)

Administrative expenses - non-recurring items

 

-

(1,420)

 

Total administrative expense

 

(3,481)

(3,837)

(8,852)

 

Operating (loss)/profit

 

(616)

229

(1,378)

 

Finance expense

 

(6)

(27)

(14)

 

(Loss)/profit before tax

 

(622)

202

(1,392)

Taxation

 

-

24

 

(Loss)/profit for the period attributable to shareholders of the parent

 

 

(622)

 

202

 

(1,368)

 

Earnings per share

 

Basic

3

(2.36p)

0.77p

(5.22p)

Diluted

(2.36p)

0.74p

(5.22p)

 

 

 

Condensed interim consolidated statement of comprehensive income

 

 

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2022

2021

2022

£'000

£'000

£'000

unaudited

unaudited

audited

 

(Loss)/profit for the period

 

(622)

202

(1,368)

 

 

Other comprehensive income:

 

Items that will be reclassified subsequently to profit or loss:

 

Exchange differences on translation of foreign operations

 

41

50

73

 

Total other comprehensive income

 

41

50

73

 

Total comprehensive (loss)/income for the year attributable to shareholders of the parent

 

 

(581)

 

252

 

(1,295)

 

 

 

Condensed interim consolidated balance sheet

 

 

31 Dec

31 Dec

30 June

2022

2021

2022

£'000

£'000

£'000

unaudited

unaudited

audited

Assets

 

Non-current assets

 

Property, plant and equipment (including right of use assets)

 

51

180

98

Goodwill and intangible assets

 

2,054

2,513

2,112

Other receivables

 

26

25

26

 

 

2,131

2,718

2,236

 

Current assets

 

Trade and other receivables

 

368

725

460

Cash and cash equivalents

 

647

2,032

915

 

 

1,015

2,757

1,375

 

Total assets

 

3,146

5,475

3,611

 

Equity and liabilities

 

Equity

 

Issued capital

 

53

52

53

Share premium

 

305

223

305

Share based payments reserve

 

341

343

341

Foreign exchange translation reserve

 

324

260

283

Retained earnings

 

(282)

2,497

340

 

 

741

3,375

1,322

 

Non-current liabilities

 

Borrowing - bank loans

 

34

47

41

Lease liabilities

 

-

37

-

 

 

34

84

41

 

Current liabilities

 

Trade and other payables

 

2,314

1,902

2,148

Borrowing - bank loans

 

13

13

13

Lease liabilities

 

44

101

87

 

 

2,371

2,016

2,248

 

Total liabilities

 

2,405

2,100

2,289

 

Total equity and liabilities

 

3,146

5,475

3,611

 

Condensed interim consolidated statement of changes in equity

 

 

Share capital

Share premium

Share based payment reserve

Foreign exchange translation reserve

Retained earnings

Total equity

 

£'000

£'000

£'000

£'000

£'000

£'000

At 1 July 2021

52

223

343

210

2,295

3,123

Profit for the period after tax

-

-

-

-

202

202

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

50

 

-

 

50

Total comprehensive income

-

-

-

50

202

252

 

 

 

 

 

 

At 31 December 2021

52

223

343

260

2,497

3,375

Transactions with equity shareholders:

Shares issued

1

82

-

-

-

83

Transfer on exercise

-

-

(2)

-

2

-

1

82

(2)

-

2

83

-

Distribution to owners

Dividends

-

-

-

-

(589)

(589)

Loss for the period after tax

-

-

-

-

(1,570)

(1,570))

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

23

 

-

 

23

Total comprehensive (loss)/income

-

-

-

23

(2,159)

(2,136)

At 30 June 2022

53

305

341

283

340

1,322

 

 

 

 

 

 

Loss for the period after tax

-

-

-

-

(622)

(622)

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

41

 

-

 

41

Total comprehensive (loss)/income

-

-

-

41

(622)

(581)

 

 

 

 

 

 

At 31 December 2022

53

305

341

324

(282)

741

 

 

Condensed interim consolidated cash flow statement

 

 

 

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2022

2021

2022

£'000

£'000

£'000

unaudited

unaudited

audited

Cash flows from operating activities

 

(Loss)/profit for the year

 

(622)

202

(1,368)

 

Net finance expense in the income statement

 

6

27

14

Depreciation of property, plant and equipment

 

53

110

181

Amortisation of intangible assets

 

91

138

256

Write off of intangible asset

 

-

-

296

Decrease / (Increase) in trade and other receivables

 

92

(94)

170

Increase in trade and other payables

 

167

16

262

 

Net cash (used) / generated by operating activities

 

(213)

399

(189)

 

Cash flows from financing activities

 

Issue of share capital

 

-

-

83

Dividend payments

 

-

-

(589)

Repayment of loans

 

(7)

(59)

(13)

Repayments of lease liabilities

 

(44)

-

(103)

Lease interest paid

 

(3)

(6)

(10)

Other interest paid

 

(3)

(21)

(4)

 

Net cash (used)/generated by financing activities

 

(57)

(86)

(636)

 

Cash flows from investing activities

 

Payments for property, plant and equipment

 

(6)

(51)

(39)

Purchase of intangibles

 

-

(160)

(114)

 

Net cash used by investing activities

 

(6)

(211)

(153)

 

Net (decrease)/increase in cash and cash equivalents

 

(276)

102

(978)

Gain / (loss) on foreign exchange

 

8

(9)

(46)

 

Net increase/(decrease) in cash and cash equivalents

 

(268)

93

(1,024)

Cash and cash equivalents at the start of the period

 

915

1,939

1,939

 

Cash and cash equivalents at the end of the period

 

647

2,032

915

 

 

1. Legal status and activities

 

The principal activity of ADVFN PLC ("the Company") and its subsidiaries (together "the Group") is the development and provision of financial information, primarily via the internet, research services and the development and exploitation of ancillary internet sites.

 

The principal trading subsidiaries are All IPO Plc, InvestorsHub.com Inc, N A Data Inc, MJAC InvestorsHub International Conferences Ltd and Cupid Bay Limited.

 

The Company is a public limited company which is quoted on the AIM of the London Stock Exchange and is incorporated and domiciled in the UK. The address of the registered office is Suite 28, Essex Business Centre, The Gables, Fyfield Road, Ongar, Essex, CM5 0GA.

 

The registered number of the company is 02374988.

 

2. Basis of preparation

 

These condensed interim financial statements have been prepared in accordance with IAS 34, "Interim Financial Reporting".

 

The financial information does not include all the information required for full annual financial statements. The same accounting policies and methods of computation have been followed in the interim financial statements as compared with the full audited financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2022, which were prepared under applicable law and in accordance with UK-adopted international accounting standards.

 

The unaudited consolidated interim financial information is for the six-month period ended 31 December 2022.

 

The financial statements are presented in Sterling (£) rounded to the nearest thousand except where specified.

 

The interim financial information has been prepared on the going concern basis which assumes the Group will continue in existence for the foreseeable future.

 

No material uncertainties that cast significant doubt about the ability of the Group to continue as a going concern have been identified by the directors. Accordingly, the directors believe it is appropriate for the interim financial statement to be prepared on the going concern basis.

 

The principle risks and uncertainties of the Company remain the same as those reported in the consolidated financial statements of the Group for the year ended 30 June 2022.

 

The interim financial information has not been audited nor has it been reviewed under ISRE 2410 of the Auditing Practices Board. The financial information presented does not constitute statutory accounts as defined by section 434 of the Companies Act 2006. The Group's statutory accounts for the year to 30 June 2022 have been filed with the Registrar of Companies. The auditors, Saffery Champness LLP reported on these accounts and their report was unqualified and did not contain a statement under section 498(2) or Section 498(3) of the Companies Act 2006.

 

 

3. Earnings per share

 

 

6 months to

6 months to

12 months to

31 Dec 2022

31 Dec 2021

30 June 2022

£'000

£'000

£'000

(Loss) / profit for the year attributable to equity shareholders

(622)

202

(1,368)

Shares

Shares

Shares

Weighted average number of shares in issue for the period

26,315,319

26,115,318

26,184,360

Dilutive effect of options

-

1,144,585

-

Weighted average shares for diluted earnings per share

26,316,319

27,259,903

26,184,360

(Loss) / earnings per share (pence)

Basic

(2.36p)

0.77p

(5.22p)

Diluted

(2.36p)

0.74p

(5.22p)

 

Where a loss has been recorded for the year the diluted loss per share does not differ from the basic loss per share. Where a profit has been recorded but the average share price for the year remains under the exercise price the existence of options is not normally dilutive. However, whilst the average exercise price of all outstanding options is above the average share price there are a number of options which are not. Under these circumstances those options where the exercise price is below the average share price are treated as dilutive.

 

 

4. Dividends

 

The directors are not recommending payment of a dividend in the current financial year.

 

5. Events after the balance sheet date

 

On 6 January 2023, the company raised £4.523m by way of an open offer of shares to qualifying shareholders. A total of 20,676,322 shares were offered to existing shareholders at a price of 33 pence per share. 13,708,300 shares were taken up.

 

6. Financial statements

Copies of these accounts are available from ADVFN Plc's registered office at Suite 28, Ongar Business Centre, The Gables, Fyfield Road, Ongar, Essex, CM5 0GA or from Companies House, Crown Way, Maindy, Cardiff, CF14 3UZ, www.companieshouse.gov.uk and from the ADVFN plc website: www.ADVFNPLC.com

 

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR QXLFBXXLXBBX
Date   Source Headline
21st Mar 20249:49 amRNSHalf-year Report
9th Feb 202411:19 amRNSNew ADVFN Italia website is launched
12th Jan 20242:00 pmRNSResult of Meeting
28th Dec 20231:10 pmRNSResult of AGM
21st Dec 20237:00 amRNSFinal Results
5th Dec 20234:00 pmRNSNotice of AGM
16th Nov 20231:30 pmRNSHolding(s) in Company
21st Sep 202312:00 pmRNSADFVN connects audience to Doceo content
15th Aug 20236:05 pmRNSCorporate update
9th Jun 20236:15 pmRNSDirector/PDMR Shareholding
2nd Jun 202312:14 pmRNSTrading and corporate update
16th May 20234:33 pmRNSHolding(s) in Company
5th May 20233:06 pmRNSTotal Voting Rights
4th Apr 20237:00 amRNSIssue of Equity
30th Mar 20232:07 pmRNSHolding(s) in Company
30th Mar 20232:05 pmRNSHolding(s) in Company
23rd Mar 20235:02 pmRNSHolding(s) in Company
23rd Mar 20235:01 pmRNSHolding(s) in Company
23rd Mar 20235:00 pmRNSHolding(s) in Company
23rd Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20236:20 pmRNSAdmission update
14th Mar 202312:05 pmRNSFurther equity issue under the Open Offer
6th Mar 20237:00 amRNSHalf-year Report
6th Feb 202311:53 amRNSDirectorate Change
13th Jan 202311:19 amRNSResult of AGM
11th Jan 20231:15 pmRNSHolding(s) in Company
11th Jan 202311:10 amRNSHolding(s) in Company
11th Jan 202311:10 amRNSHolding(s) in Company
11th Jan 202310:49 amRNSHolding(s) in Company
11th Jan 202310:49 amRNSHolding(s) in Company
10th Jan 20237:00 amRNSCorporate update
9th Jan 20235:22 pmRNSTotal voting rights, Director / PDMR shareholding
6th Jan 20232:04 pmRNSFinal Results of Open Offer
6th Jan 20237:00 amRNSResults of Open Offer
20th Dec 20227:00 amRNSOpen Offer timetable and AGM
6th Dec 20227:00 amRNSOpen Offer
6th Dec 20227:00 amRNSFinal Results
28th Nov 20227:00 amRNSCorporate update
15th Sep 202210:45 amRNSAppointment of joint corporate broker
19th Aug 20224:15 pmRNSCorporate update
8th Aug 20227:00 amRNSDirectorate Change
6th Jun 20227:00 amRNSTrading and Corporate Update
29th Apr 20222:05 pmRNSResult of Meeting
28th Apr 20224:41 pmRNSSecond Price Monitoring Extn
28th Apr 20224:35 pmRNSPrice Monitoring Extension
28th Apr 20222:01 pmRNSHolding(s) in Company
22nd Apr 20224:00 pmRNSTotal Voting Rights
20th Apr 202211:05 amRNSSecond Price Monitoring Extn
20th Apr 202211:00 amRNSPrice Monitoring Extension
13th Apr 20229:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.